Conference Track

First-line Therapy and Switch Strategies

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Rates of Treatment Failure in Rio de Janeiro Not Associated With Generic Drug Use or Type of Treatment Setting
Once-Daily Efavirenz-Based Regimens Appear Safe and Effective in Antiretroviral-Naive Patients
Lopinavir/Ritonavir- and Efavirenz-Based Initial Regimens Most Effective in Retrospective Analysis
Tenofovir Plus Emtricitabine Superior to Fixed-Dose Zidovudine/Lamivudine, Each With Efavirenz, in Antiretroviral Therapy-Naive Patients
Differing Perceptions of Treatment-Experienced Patients vs Physicians on Initiating Injectable Antiretroviral Drug Therapy
Ritonavir-Boosted Atazanavir Maintenance Therapy Sustains Virologic Suppression in Plasma, But Lower Rates of Suppression in Semen, CSF
Efficacy of Zidovudine/Lamivudine/Efavirenz Similar to Tenofovir/Lamivudine/Efavirenz in Observational Treatment-Naive Cohort
Simplification to Lopinavir/Ritonavir Monotherapy Maintains Virologic Control Similar to Continued HAART Over 48 Weeks
No Progression of Bone Mineral Density Loss or Lipodystrophy After 4 Years of Sustained Virologic Response with Tenofovir, Lamivudine, and Efavirenz
Switch From Stable PI-Based to Atazanavir-Based Regimen Reduces Risk of Viral Rebound and Improves Lipid Profile

Expert Analysis

First-line Therapy and Switch Strategies

Program Director: John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPH
W. David Hardy, MD
Mauro Schechter, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss treatment outcomes observed in patients initiating antiretroviral therapy in resource-limited countries.
Explain the results of trials investigating outcomes in patients modifying antiretroviral therapy to manage toxicity.
Describe recent data on immunologic parameters for initiation of antiretroviral therapy.
Recount key efficacy and safety data from recent clinical trials comparing first-line antiretroviral regimens.

CME CREDIT INFORMATION

Release Date: 10/07/05

Expiration Date: 10/06/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.7 Nursing CE credits

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.